Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

yonkenafil

Known as: 2-(2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)phenyl)-5-methyl-7-propyl-3H-pyrrolo(2,3-d)pyrimidin-4(7H)-one 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyrimidinonesPyrroles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Inhibition of PDE5 attenuates streptozotocin-induced neuroinflammation and tau hyperphosphorylation in a streptozotocin-treated rat model
Intracerebroventricular (icv) streptozotocin (STZ) injection decreases cerebral insulin signal pathway function and produces… Expand
2016
2016
Rapid and sensitive liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of yonkenafil and its major metabolites in rat plasma.
Yonkenafil is a promising drug for treatment of male erectile dysfunction. Previous studies showed that the piperazine-N,N… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
2015
2015
A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model
In Alzheimer's disease (AD), activated microglia invade and surround β-amyloid plaques, possibly contributing to the aggregation… Expand
2015
2015
NF-κB Upregulates Type 5 Phosphodiesterase in N9 Microglial Cells: Inhibition by Sildenafil and Yonkenafil
Our previous studies showed that the phosphodiesterase-5 (PDE5) inhibitor sildenafil inhibited the microglial activation induced… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
2014
2014
Yonkenafil: A novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke
  • Xuemei Chen, Nannan Wang, +6 authors Jingyu Yang
  • Experimental Neurology
  • 2014
    • Corpus ID: 24713194
Yonkenafil is a novel phosphodiesterase type 5 (PDE5) inhibitor. Here we evaluated the effect of yonkenafil on ischemic injury… Expand
2008
2008
A rapid and sensitive LC-MS/MS assay to quantify yonkenafil in rat plasma with application to preclinical pharmacokinetics studies.
A novel method for the quantitation of yonkenafil, a new synthetic phosphodiesterase V inhibitor, in rat plasma using high… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE